ACE Inhibitors and ARBs in Diabetic Patients
Introduction to ACE Inhibitors and ARBs
- The American Diabetes Association recommends ACE inhibitors or ARBs for nonpregnant diabetic patients with hypertension and moderately increased albuminuria (Grade B recommendation) 2
- ACE inhibitor or ARB therapy at maximum tolerated doses has reduced progression to more advanced albuminuria, slowed CKD progression, and reduced cardiovascular events in diabetic patients with moderately increased albuminuria 1
Evidence Against Use in Normoalbuminuric Patients
- In type 2 diabetic patients with normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but actually increased the rate of cardiovascular events 1
- In type 1 diabetic patients exhibiting neither albuminuria nor hypertension, ACE inhibitors or ARBs did not prevent the development of glomerulopathy as assessed by kidney biopsy 1
Benefits of ACE Inhibitors and ARBs
- ACE inhibitors or ARBs are strongly recommended (Grade A) to prevent progression of kidney disease and reduce cardiovascular events in diabetic patients with severely increased albuminuria (≥300 mg/g creatinine) and/or eGFR <60 mL/min/1.73 m² 2
- Among patients with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73 m² and UACR ≥300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD 1, 3
Clinical Algorithm for Decision-Making
- Measure spot urinary albumin-to-creatinine ratio (UACR) annually in all diabetic patients 2
- UACR <30 mg/g (normoalbuminuria): Use any first-line antihypertensive class for blood pressure control; ACE inhibitors/ARBs offer no kidney-specific advantage 1
- UACR 30-299 mg/g (moderately increased): Consider ACE inhibitor or ARB at maximum tolerated dose to prevent progression to macroalbuminuria and reduce cardiovascular events 1, 2
- UACR ≥300 mg/g and/or eGFR <60 mL/min/1.73 m²: Strongly recommend ACE inhibitor or ARB as first-line therapy 2
Important Caveats and Monitoring
- A blood pressure level <130/80 mmHg is recommended to reduce cardiovascular mortality and slow CKD progression among all diabetic patients 1
- The combined use of ACE inhibitors and ARBs should be avoided—it increases adverse events (hyperkalemia and/or acute kidney injury) without additional benefits on cardiovascular or CKD outcomes 3, 4
- Monitor serum potassium and creatinine within 2-4 weeks of initiation or dose change 4